Several repurposed antiparasitic agents have demonstrated preclinical activity targeting cancer stem cells (CSCs) and tumor-initiating populations by disrupting self-renewal transcription factors, developmental signaling cascades, and cellular bioenergetics:
Antiparasitic Cancer Therapy


